Hematologic Neoplasms: Clinical Trials

44 trials for Hematologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

44 unknown. 44 Phase 2, 22 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 244Unknown 44
Phase 122Unknown 22
Phase 33Unknown 3

Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
Thymoglobulin Injectable Product - Hematological Malignancy
Phase 2UnknownInstitut Paoli-Calmettes272024-03-312024-02-20
Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade
Cyclophosphamid - Graft-versus-host Disease, Hematological Malignancies
Phase 2UnknownBeijing 302 Hospital222024-02-282024-02-20
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Allogeneic T cell progenitors, cultured ex-vivo - Hematological Malignancies
Phase 1 / Phase 2UnknownSmart Immune SAS402023-06-062023-09-25
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
umbilical cord derived mesenchymal stem cells - Hematologic Neoplasms, Neutropenia
Phase 1 / Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1812023-01-012023-01-05
Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome
Ruxolitinib - Bronchiolitis Obliterans Syndrome, Hematologic Malignancy
Phase 2UnknownFirst Affiliated Hospital of Zhejiang University502022-06-012022-10-19
Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation - Hematologic Malignancy
Phase 1 / Phase 2UnknownSichuan University562022-03-012022-03-15
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
MIT-001, normal saline - Oral Mucositis, Lymphoma
Phase 2UnknownMitoImmune Therapeutics602022-02-012024-05-29
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
CN202 - Locally Advanced Solid Tumor, Metastatic Solid Tumor
Phase 1 / Phase 2UnknownCuron Biopharmaceutical (Australia) Co Pty Ltd1642021-10-222021-08-31
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
venetoclax combining with fludarabine and melphalan - Hematologic Malignancy, Older Patients
Phase 2UnknownFirst Affiliated Hospital of Zhejiang University502021-10-072021-10-27
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
Azacitidine, all trans retinoic acid - AML, MDS
Phase 2 / Phase 3UnknownThe First Affiliated Hospital of Soochow University1802021-05-012022-01-03
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
Azacitidine in Combination With Venetoclax - Hematologic Malignancy, Stem Cell Transplant Complications
Phase 2UnknownFirst Affiliated Hospital of Zhejiang University952021-03-192023-02-21
Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
CAR-T cells - Hematological Malignancies
Phase 1 / Phase 2UnknownZhejiang University502021-03-012021-03-10
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Cyclophosphamide-Fludarabine (Cy/Flu), oNKord® - Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownGlycostem Therapeutics BV332020-12-082022-06-21
GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide
Methotrexate Injectable Solution - Graft Vs Host Disease, Hematopoietic Neoplasm
Phase 1 / Phase 2UnknownUniversity of Sao Paulo General Hospital472020-10-072021-09-14
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
CAR-T cell therapy - Hematological Malignancy
Phase 2 / Phase 3UnknownShanxi Bethune Hospital302020-06-152024-02-02
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents - Solid Tumor, Hematological Malignancy
Phase 1 / Phase 2UnknownChinese PLA General Hospital302019-09-152022-04-13
Combination Chemotherapy in Patients With Newly Diagnosed BPDCN
Chemotherapy - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 2UnknownCentre Hospitalier Universitaire de Besancon262019-05-022024-02-08
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
donor-derived CIK cells - Relapsed Hematologic Malignancy
Phase 1 / Phase 2UnknownA.O. Ospedale Papa Giovanni XXIII202019-01-132021-12-23
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT
Imipenem - Antibacterial Prophylaxis, Hematological Malignancies
Phase 2 / Phase 3UnknownNanfang Hospital, Southern Medical University2502018-12-012018-11-07
Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT
Cholecalciferol - Hematologic Neoplasms
Phase 2UnknownSeoul National University Hospital882017-10-012017-10-25

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Graft vs Host Disease (4)  ·  Leukemia, Myeloid, Acute (4)  ·  Lymphoma, Mantle-Cell (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma, Follicular (3)  ·  Lymphoma, Large B-Cell, Diffuse (3)  ·  Multiple Myeloma (3)  ·  Polycythemia Vera (3)  ·  Recurrence (3)  ·  Leukemia (2)  ·  Leukemia, Prolymphocytic (2)  ·  Lymphoma (2)  ·  Myelodysplastic Syndromes (2)  ·  Neoplasms (2)

Broader conditions

Hemic and Lymphatic Diseases (44)  ·  Neoplasms by Site (44)  ·  Hematologic Diseases (43)  ·  Neoplasms (42)  ·  Immune System Diseases (12)  ·  Neoplasms by Histologic Type (11)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Pathologic Processes (10)  ·  Immunoproliferative Disorders (7)  ·  Leukemia (7)  ·  Lymphatic Diseases (7)  ·  Lymphoproliferative Disorders (7)  ·  Bone Marrow Diseases (6)  ·  Disease Attributes (6)  ·  Lymphoma (6)

Interventions

Cyclophosphamide (4)  ·  fludarabine (3)  ·  Azacitidine (2)  ·  Immunotherapy, Adoptive (2)  ·  Mycophenolic Acid (2)  ·  Antilymphocyte Serum (1)  ·  Busulfan (1)  ·  CF regimen (1)  ·  Cholecalciferol (1)  ·  Cord Blood Stem Cell Transplantation (1)  ·  Cyclosporine (1)  ·  Drug Therapy (1)  ·  Etanercept (1)  ·  Hematopoietic Stem Cell Transplantation (1)  ·  Histone Deacetylase Inhibitors (1)

Sponsors

Chinese PLA General Hospital (4)  ·  First Affiliated Hospital of Zhejiang University (3)  ·  A.O. Ospedale Papa Giovanni XXIII (2)  ·  Hospices Civils de Lyon (2)  ·  Ronald Hoffman (2)  ·  Seoul National University Hospital (2)  ·  Beijing 302 Hospital (1)  ·  Cancer Research UK (1)  ·  Cellect Biotechnology (1)  ·  Centre Hospitalier Universitaire de Besancon (1)  ·  Ciusss de L'Est de l'Île de Montréal (1)  ·  Copenhagen University Hospital at Herlev (1)  ·  Curon Biopharmaceutical (Australia) Co Pty Ltd (1)  ·  European Institute of Oncology (1)  ·  Glycostem Therapeutics BV (1)

Countries

China (15)  ·  France (6)  ·  Italy (5)  ·  Israel (3)  ·  South Korea (3)  ·  Belgium (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  Denmark (1)  ·  Germany (1)  ·  Sweden (1)

Top investigators

Yi Luo, M.D. (3)  ·  Alessandro Rambaldi, MD (2)  ·  Ronald Hoffman, MD (2)  ·  Andrea Velardi, Prof (1)  ·  David Ritchie, FRACP, PhD (1)  ·  Denis-Claude Roy, MD PhD (1)  ·  Domenico Russo, Full Professor (1)  ·  Gary Richardson (1)  ·  Giancarlo Fatobene, MD (1)  ·  Han Yue, Ph.D (1)  ·  Hans C Hasselbalch, MD (1)  ·  Jiang Cao, Doctor (1)

Results publications

PMID 12171484, PMID 16732175, PMID 18468541, PMID 18703664, PMID 18820709, PMID 20350611, PMID 21393326, PMID 21417678, PMID 24140121, PMID 25444722, PMID 25563429, PMID 29263894, PMID 32245502, PMID 34515338, PMID 34700343, PMID 38304826, PMID 38485149, PMID 42159161

NIH funding

2009 (1), 2019 (1), P01CA108671 (1)